GlassScriptPhysician profile
Anuj Kunadia
NPI 1881343572
$4,318.55
in general payments reported to CMS, 2019-2025
20 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,035 · 2024: $1,889 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,219 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,218.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $466.05 | 2023-2025 | Bimzelx |
| Lilly USA, LLC | $400.53 | 2023-2024 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $347.09 | 2023-2025 | Zoryve |
| Genzyme Corporation | $345.48 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.78 | 2023-2025 | Spevigo |
| Organogenesis INC. | $258.19 | 2023-2024 | Puraply |
| Abbvie INC. | $257.38 | 2024 | |
| Janssen Biotech, INC. | $249.61 | 2025 | Tremfya |
| Kyowa Kirin, INC. | $248.72 | 2023-2025 | Poteligeo |
| Dermavant Sciences, INC. | $225.53 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $207.91 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $188.33 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $144.35 | 2024 | Uvadex |
| Janssen Scientific Affairs, LLC | $140.97 | 2025 | Tremfya |
| Therakos LLC | $130.35 | 2025 | Uvadex, Cellex |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $122.19 | 2025 | Ycanth |
| Pfizer INC. | $117.32 | 2025 | |
| Galderma Laboratories, L.P. | $100.29 | 2024 | |
| Sun Pharmaceutical Industries INC. | $50.18 | 2024 | |
| Leo Pharma INC. | $23.30 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Kunadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.